Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Malignant Lymphoma

  Free Subscription

Articles published in Leukemia

Retrieve available abstracts of 89 articles:
HTML format

Single Articles

    June 2022
  1. THUS YJ, Eldering E, Kater AP, Spaargaren M, et al
    Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma.
    Leukemia. 2022 Jun 20. pii: 10.1038/s41375-022-01627.
    PubMed     Abstract available

  2. LAUER EM, Mutter J, Scherer F
    Circulating tumor DNA in B-cell lymphoma: technical advances, clinical applications, and perspectives for translational research.
    Leukemia. 2022 Jun 14. pii: 10.1038/s41375-022-01618.
    PubMed     Abstract available

  3. DONG G, Liu X, Wang L, Yin W, et al
    Genomic profiling identifies distinct genetic subtypes in extra-nodal natural killer/T-cell lymphoma.
    Leukemia. 2022 Jun 13. pii: 10.1038/s41375-022-01623.
    PubMed     Abstract available

    May 2022
  4. FERRERI AJM, Cwynarski K, Pulczynski E, Fox CP, et al
    Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
    Leukemia. 2022 May 13. pii: 10.1038/s41375-022-01582.
    PubMed     Abstract available

  5. KAMEDA K, Kako S, Kim SW, Usui Y, et al
    Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL.
    Leukemia. 2022;36:1361-1370.
    PubMed     Abstract available

    April 2022
  6. ZHOU W, Xu Y, Zhang J, Zhang P, et al
    MiRNA-363-3p/DUSP10/JNK axis mediates chemoresistance by enhancing DNA damage repair in diffuse large B-cell lymphoma.
    Leukemia. 2022 Apr 29. pii: 10.1038/s41375-022-01565.
    PubMed     Abstract available

  7. WONG J, Gruber E, Maher B, Waltham M, et al
    Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma.
    Leukemia. 2022 Apr 22. pii: 10.1038/s41375-022-01571.
    PubMed     Abstract available

  8. BAZARBACHI A, Boumendil A, Finel H, Khvedelidze I, et al
    The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years.
    Leukemia. 2022 Apr 12. pii: 10.1038/s41375-022-01563.
    PubMed     Abstract available

    March 2022
  9. DINNESSEN MAW, Maas CCHM, Tonino SH, Visser O, et al
    Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era.
    Leukemia. 2022 Mar 4. pii: 10.1038/s41375-022-01535.

    February 2022
  10. DAHL M, Husby S, Eskelund CW, Besenbacher S, et al
    Correction: Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
    Leukemia. 2022 Feb 18. pii: 10.1038/s41375-022-01526.

  11. MARCHESI F, Pimpinelli F, Giannarelli D, Ronchetti L, et al
    Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.
    Leukemia. 2022;36:588-590.

    January 2022
  12. LIM TL, Lieberman DB, Davis AR, Loren AW, et al
    Germline POT1 variants can predispose to myeloid and lymphoid neoplasms.
    Leukemia. 2022;36:283-287.

    November 2021
  13. BERTRAM K, Leary PJ, Boudesco C, Fullin J, et al
    Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models.
    Leukemia. 2021 Nov 18. pii: 10.1038/s41375-021-01470.
    PubMed     Abstract available

  14. REUTTER K, Sandmann S, Rohde J, Muller S, et al
    Publisher Correction: Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma.
    Leukemia. 2021 Nov 16. pii: 10.1038/s41375-021-01359.

  15. SPANJAART AM, Ljungman P, de La Camara R, Tridello G, et al
    Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European He
    Leukemia. 2021 Nov 8. pii: 10.1038/s41375-021-01466.

    October 2021
  16. NEWMAN AM, Zaka M, Zhou P, Blain AE, et al
    Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma.
    Leukemia. 2021 Oct 21. pii: 10.1038/s41375-021-01444.
    PubMed     Abstract available

  17. BROCKELMANN PJ, Muller H, Gillessen S, Yang X, et al
    Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysis.
    Leukemia. 2021 Oct 9. pii: 10.1038/s41375-021-01442.
    PubMed     Abstract available

    September 2021
  18. GARCIA-MARQUEZ MA, Thelen M, Reinke S, Keller D, et al
    Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma.
    Leukemia. 2021 Sep 28. pii: 10.1038/s41375-021-01421.
    PubMed     Abstract available

  19. TAMAKI K, Morishima S, Suzuki S, Shigenari A, et al
    Full-length HLA sequencing in adult T cell leukemia-lymphoma uncovers multiple gene alterations.
    Leukemia. 2021 Sep 13. pii: 10.1038/s41375-021-01403.

  20. WANG H, Fu BB, Gale RP, Liang Y, et al
    NK-/T-cell lymphomas.
    Leukemia. 2021;35:2460-2468.
    PubMed     Abstract available

    August 2021
  21. VILARRASA-BLASI R, Verdaguer-Dot N, Belver L, Soler-Vila P, et al
    Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma.
    Leukemia. 2021 Aug 28. pii: 10.1038/s41375-021-01389.

  22. DAMASCHIN C, Goergen H, Kreissl S, Plutschow A, et al
    Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group.
    Leukemia. 2021 Aug 18. pii: 10.1038/s41375-021-01386.

  23. YANG Y, Wang Y, Liu X, He X, et al
    Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
    Leukemia. 2021 Aug 2. pii: 10.1038/s41375-021-01371.

    July 2021
  24. ROSSI A, Orecchioni S, Falvo P, Tabanelli V, et al
    Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
    Leukemia. 2021 Jul 24. pii: 10.1038/s41375-021-01347.
    PubMed     Abstract available

  25. LOWENBERG B, Kersten MJ, Gale RP, van Oers M, et al
    Prof. Anton Hagenbeek 1948-2021: Father of MRD and Lymphoma Expert.
    Leukemia. 2021 Jul 20. pii: 10.1038/s41375-021-01310.

  26. ZHANG Y, Wang Y, Liu Y, Tong C, et al
    Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.
    Leukemia. 2021 Jul 16. pii: 10.1038/s41375-021-01345.
    PubMed     Abstract available

  27. DAHL M, Husby S, Eskelund CW, Besenbacher S, et al
    Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.
    Leukemia. 2021 Jul 9. pii: 10.1038/s41375-021-01311.
    PubMed     Abstract available

  28. PRITCHETT JC, Yang ZZ, Kim HJ, Villasboas JC, et al
    High-dimensional and single-cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL).
    Leukemia. 2021 Jul 6. pii: 10.1038/s41375-021-01321.
    PubMed     Abstract available

  29. HUBSCHMANN D, Kleinheinz K, Wagener R, Bernhart SH, et al
    Mutational mechanisms shaping the coding and noncoding genome of germinal center derived B-cell lymphomas.
    Leukemia. 2021;35:2002-2016.
    PubMed     Abstract available

  30. SASI B, Ethiraj P, Myers J, Lin AP, et al
    Regulation of PD-L1 expression is a novel facet of cyclic-AMP-mediated immunosuppression.
    Leukemia. 2021;35:1990-2001.
    PubMed     Abstract available

    June 2021
  31. GRAHAM CE, Jozwik A, Quartey-Papafio R, Ioannou N, et al
    Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
    Leukemia. 2021 Jun 18. pii: 10.1038/s41375-021-01324.

  32. JACHIMOWICZ RD, Klapper W, Glehr G, Muller H, et al
    Gene expression-based outcome prediction in advanced stage classical Hodgkin lymphoma treated with BEACOPP.
    Leukemia. 2021 Jun 10. pii: 10.1038/s41375-021-01314.

  33. POGLIO S, Prochazkova-Carlotti M, Cherrier F, Gros A, et al
    Xenograft and cell culture models of Sezary syndrome reveal cell of origin diversity and subclonal heterogeneity.
    Leukemia. 2021;35:1696-1709.
    PubMed     Abstract available

    May 2021
  34. LITTLE MP, Wakeford R, Zablotska LB, Borrego D, et al
    Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age.
    Leukemia. 2021 May 28. pii: 10.1038/s41375-021-01284.
    PubMed     Abstract available

  35. WU F, Watanabe N, Tzioni MM, Akarca A, et al
    Thyroid MALT lymphoma: self-harm to gain potential T-cell help.
    Leukemia. 2021 May 21. pii: 10.1038/s41375-021-01289.
    PubMed     Abstract available

  36. HE MY, Kridel R
    Treatment resistance in diffuse large B-cell lymphoma.
    Leukemia. 2021 May 20. pii: 10.1038/s41375-021-01285.
    PubMed     Abstract available

  37. GOLDMAN S, Barth M, Shiramizu B, Shi Q, et al
    A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
    Leukemia. 2021 May 3. pii: 10.1038/s41375-021-01256.

    April 2021
  38. CHIHARA D, Miljkovic M, Iyer SP, Vega F, et al
    Targeted based therapy in nodal T-cell lymphomas.
    Leukemia. 2021;35:956-967.
    PubMed     Abstract available

    March 2021
  39. VALERO JG, Matas-Cespedes A, Arenas F, Rodriguez V, et al
    The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma.
    Leukemia. 2021 Mar 17. pii: 10.1038/s41375-021-01201.
    PubMed     Abstract available

  40. LIM JQ, Huang D, Tang T, Tan D, et al
    Correction to: Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.
    Leukemia. 2021 Mar 8. pii: 10.1038/s41375-021-01195.

  41. WENIGER MA, Kuppers R
    Molecular biology of Hodgkin lymphoma.
    Leukemia. 2021 Mar 8. pii: 10.1038/s41375-021-01204.
    PubMed     Abstract available

  42. MERRYMAN RW, Castagna L, Giordano L, Ho VT, et al
    Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
    Leukemia. 2021 Mar 3. pii: 10.1038/s41375-021-01193.
    PubMed     Abstract available

  43. FISKUS W, Mill CP, Perera D, Birdwell C, et al
    BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
    Leukemia. 2021 Mar 2. pii: 10.1038/s41375-021-01181.
    PubMed     Abstract available

  44. REUKEN PA, Stallmach A, Pletz MW, Brandt C, et al
    Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection.
    Leukemia. 2021;35:920-923.

  45. ARMAND P, Lesokhin A, Borrello I, Timmerman J, et al
    A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
    Leukemia. 2021;35:777-786.
    PubMed     Abstract available

    February 2021
  46. GOUVEIA MH, Otim I, Ogwang MD, Wang M, et al
    Author Correction to: Endemic Burkitt lymphoma in second-degree relatives in Northern Uganda: in-depth genome-wide analysis suggests clues about genetic susceptibility.
    Leukemia. 2021 Feb 1. pii: 10.1038/s41375-021-01140.

  47. LI X, Daniyan AF, Lopez AV, Purdon TJ, et al
    Cytokine IL-36gamma improves CAR T-cell functionality and induces endogenous antitumor response.
    Leukemia. 2021;35:506-521.
    PubMed     Abstract available

  48. HARTERT KT, Wenzl K, Krull JE, Manske M, et al
    Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.
    Leukemia. 2021;35:522-533.
    PubMed     Abstract available

    January 2021
  49. VISCO C, Di Rocco A, Evangelista A, Quaglia FM, et al
    Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
    Leukemia. 2021 Jan 22. pii: 10.1038/s41375-020-01119.

    December 2020
  50. MORSCHHAUSER F, Dyer MJS, Walter HS, Danilov AV, et al
    Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma.
    Leukemia. 2020 Dec 17. pii: 10.1038/s41375-020-01108.

  51. MOMBLED M, Rodriguez L, Avalon M, Duchez P, et al
    Characteristics of cells with engraftment capacity within CD34+ cell population upon G-CSF and Plerixafor mobilization.
    Leukemia. 2020;34:3370-3381.
    PubMed     Abstract available

  52. VEAZEY KJ, Cheng D, Lin K, Villarreal OD, et al
    CARM1 inhibition reduces histone acetyltransferase activity causing synthetic lethality in CREBBP/EP300-mutated lymphomas.
    Leukemia. 2020;34:3269-3285.
    PubMed     Abstract available

    November 2020
  53. LOBELLO C, Tichy B, Bystry V, Radova L, et al
    STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma.
    Leukemia. 2020 Nov 27. pii: 10.1038/s41375-020-01093.

  54. WANG H, Wei W, Zhang JP, Song Z, et al
    A novel model of alternative NF-kappaB pathway activation in anaplastic large cell lymphoma.
    Leukemia. 2020 Nov 12. pii: 10.1038/s41375-020-01088.
    PubMed     Abstract available

  55. YANG C, Xie M, Zhang K, Liu H, et al
    Risk of HBV reactivation post CD19-CAR-T cell therapy in DLBCL patients with concomitant chronic HBV infection.
    Leukemia. 2020;34:3055-3059.

  56. LIBERT D, Yuan CM, Masih KE, Galera P, et al
    Serial evaluation of CD19 surface expression in pediatric B-cell malignancies following CD19-targeted therapy.
    Leukemia. 2020;34:3064-3069.

    October 2020
  57. ZENT CS, Brady MT, Delage C, Strawderman M, et al
    Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma.
    Leukemia. 2020 Oct 30. pii: 10.1038/s41375-020-01074.

  58. GOUVEIA MH, Otim I, Ogwang MD, Mingyi W, et al
    Endemic Burkitt Lymphoma in second-degree relatives in Northern Uganda: in-depth genome-wide analysis suggests clues about genetic susceptibility.
    Leukemia. 2020 Oct 13. pii: 10.1038/s41375-020-01052.

  59. DINNESSEN MAW, van der Poel MWM, Tonino SH, Visser O, et al
    Stage-specific trends in primary therapy and survival in follicular lymphoma: a nationwide population-based analysis in the Netherlands, 1989-2016.
    Leukemia. 2020 Oct 12. pii: 10.1038/s41375-020-01048.
    PubMed     Abstract available

  60. WANG L, Wang JW
    PD-1 blockade in extranodal NK/T-cell lymphoma: who is in charge?
    Leukemia. 2020 Oct 2. pii: 10.1038/s41375-020-01046.

  61. WANG Y, Liu Y, Tan X, Pan B, et al
    Safety and efficacy of chimeric antigen receptor (CAR)-T-cell therapy in persons with advanced B-cell cancers and hepatitis B virus-infection.
    Leukemia. 2020;34:2704-2707.
    PubMed     Abstract available

  62. BALINAS-GAVIRA C, Rodriguez MI, Andrades A, Cuadros M, et al
    Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL.
    Leukemia. 2020;34:2722-2735.
    PubMed     Abstract available

    September 2020
  63. YANG Y, Wang Y, Liu X, He X, et al
    Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
    Leukemia. 2020 Sep 17. pii: 10.1038/s41375-020-01042.
    PubMed     Abstract available

  64. KURODA Y, Yashima-Abo A, Koyama D, Kikuchi J, et al
    Bone marrow stromal cell-mediated degradation of CD20 leads to primary rituximab resistance in mantle cell lymphoma.
    Leukemia. 2020 Sep 14. pii: 10.1038/s41375-020-01035.

  65. JUNCO JJ, Chen T, Rashid R, Terrell M, et al
    An Mb1-Cre-driven oncogenic Kras mutation results in a mouse model of T-acute lymphoblastic leukemia/lymphoma with short latency and high penetrance.
    Leukemia. 2020 Sep 11. pii: 10.1038/s41375-020-01036.

    August 2020
  66. NIE K, Redmond D, Eng KW, Zhang T, et al
    Mutation landscape, clonal evolution pattern, and potential pathogenic pathways in B-lymphoblastic transformation of follicular lymphoma.
    Leukemia. 2020 Aug 12. pii: 10.1038/s41375-020-01014.

  67. VISCO C, Di Rocco A, Evangelista A, Quaglia FM, et al
    Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study.
    Leukemia. 2020 Aug 11. pii: 10.1038/s41375-020-01013.
    PubMed     Abstract available

  68. LIM JQ, Huang D, Tang T, Tan D, et al
    Whole-genome sequencing identifies responders to Pembrolizumab in relapse/refractory natural-killer/T cell lymphoma.
    Leukemia. 2020 Aug 5. pii: 10.1038/s41375-020-1000.

  69. BURKE GAA, Beishuizen A, Bhojwani D, Burkhardt B, et al
    Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy.
    Leukemia. 2020;34:2271-2275.

    July 2020
  70. CHIBA S, Sakata-Yanagimoto M
    Advances in understanding of angioimmunoblastic T-cell lymphoma.
    Leukemia. 2020 Jul 23. pii: 10.1038/s41375-020-0990.
    PubMed     Abstract available

  71. PRUTSCH N, Gurnhofer E, Suske T, Liang HC, et al
    Correction: Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
    Leukemia. 2020 Jul 14. pii: 10.1038/s41375-020-0968.
    PubMed     Abstract available

  72. GUAN P, Dong T, Zhang L, Zhao S, et al
    Staging challenges in extranasal and juvenile extranodal NK/T-cell lymphoma.
    Leukemia. 2020 Jul 14. pii: 10.1038/s41375-020-0975.

  73. ZHU J, Yang Y, Tao J, Wang SL, et al
    Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review.
    Leukemia. 2020 Jul 10. pii: 10.1038/s41375-020-0963.
    PubMed     Abstract available

    June 2020
  74. LANTERMANS HC, Minderman M, Kuil A, Kersten MJ, et al
    Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.
    Leukemia. 2020 Jun 26. pii: 10.1038/s41375-020-0934.
    PubMed     Abstract available

  75. MARCAIS A, Lhermitte L, Artesi M, Laurent C, et al
    Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia/lymphoma and defines an unfavorable indolent subtype.
    Leukemia. 2020 Jun 17. pii: 10.1038/s41375-020-0900.
    PubMed     Abstract available

    May 2020
  76. DRIESSEN J, Visser O, Zijlstra JM, Lugtenburg PJ, et al
    Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.
    Leukemia. 2020 May 28. pii: 10.1038/s41375-020-0875.
    PubMed     Abstract available

  77. REUTTER K, Sandmann S, Rohde J, Muller S, et al
    Reconstructing clonal evolution in relapsed and non-relapsed Burkitt lymphoma.
    Leukemia. 2020 May 14. pii: 10.1038/s41375-020-0862.

  78. YOUNG KH
    Good prognosis or poor prognosis, dose-intensive or less intensive: who decides for adults with T-lymphoblastic lymphoma/leukemia.
    Leukemia. 2020 May 12. pii: 10.1038/s41375-020-0861.

  79. ATTARBASCHI A, Carraro E, Ronceray L, Andres M, et al
    Second malignant neoplasms after treatment of non-Hodgkin's lymphoma-a retrospective multinational study of 189 children and adolescents.
    Leukemia. 2020 May 11. pii: 10.1038/s41375-020-0841.
    PubMed     Abstract available

  80. WULF GG, Altmann B, Ziepert M, D'Amore F, et al
    Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.
    Leukemia. 2020 May 7. pii: 10.1038/s41375-020-0838.
    PubMed     Abstract available

  81. CUCCO F, Barrans S, Sha C, Clipson A, et al
    Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.
    Leukemia. 2020;34:1329-1341.
    PubMed     Abstract available

  82. HU G, Phillips JL, Dasari S, Jacobs HK, et al
    Targetability of STAT3-JAK2 fusions: implications for T-cell lymphoproliferative disorders of the gastrointestinal tract.
    Leukemia. 2020;34:1467-1471.

  83. DUPLOYEZ N, Goursaud L, Fenwarth L, Bories C, et al
    Familial myeloid malignancies with germline TET2 mutation.
    Leukemia. 2020;34:1450-1453.

    April 2020
  84. NAKAMURA K, Casey M, Oey H, Vari F, et al
    Targeting an adenosine-mediated "don't eat me signal" augments anti-lymphoma immunity by anti-CD20 monoclonal antibody.
    Leukemia. 2020 Apr 8. pii: 10.1038/s41375-020-0811.
    PubMed     Abstract available

    March 2020
  85. AL-SAWAF O, Robrecht S, Bahlo J, Fink AM, et al
    Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials.
    Leukemia. 2020 Mar 17. pii: 10.1038/s41375-020-0797.
    PubMed     Abstract available

  86. HERBRUEGGEN H, Mueller S, Rohde J, Arias Padilla L, et al
    Treatment and outcome of IG-MYC(+) neoplasms with precursor B-cell phenotype in childhood and adolescence.
    Leukemia. 2020;34:942-946.

    February 2020
  87. GUO F, Luo Y, Jiang X, Lu X, et al
    Recent BCR stimulation induces a negative autoregulatory loop via FBXO10 mediated degradation of HGAL.
    Leukemia. 2020;34:553-566.
    PubMed     Abstract available

  88. POTT C, Sehn LH, Belada D, Gribben J, et al
    MRD response in relapsed/refractory FL after obinutuzumab plus bendamustine or bendamustine alone in the GADOLIN trial.
    Leukemia. 2020;34:522-532.
    PubMed     Abstract available

    January 2020
  89. ZHANG X, Bi C, Lu T, Zhang W, et al
    Targeting translation initiation by synthetic rocaglates for treating MYC-driven lymphomas.
    Leukemia. 2020;34:138-150.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.